Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 5/20 | 0.38 |
| ▸ | CCND1 | P24385 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23473991 | 0.84 | ALDH1A1 (0.43) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL13544179 | 0.84 | ALDH1A1 (0.47) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL1286353 | 0.81 | ALDH1A1 (0.41) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL5355865 | 0.81 | ALDH1A1 (0.44) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL24122690 | 0.81 | ALDH1A1 (0.44) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL13351381 | 0.81 | ALDH1A1 (0.41) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL17595095 | 0.81 | ALDH1A1 (0.41) | HTTALDH1A1CYP1A2PARP1TYMS | |
| SCHEMBL7045022 | 0.79 | CYP1A2 (0.40) | HTTALDH1A1CYP1A2KDM4EGRIN2D | |
| SCHEMBL1285923 | 0.78 | KDM4E (0.43) | HTTALDH1A1PARP1TYMSKDM4E | |
| SCHEMBL23478355 | 0.78 | ALDH1A1 (0.39) | HTTALDH1A1CYP1A2PARP1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-9670463-B2 | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9394310-B2 | Carbocycle-substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-04-28 | — | — | US | disclosed |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2016-02-18 | — | — | US | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014153001-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140242046-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | Childern's Medical Center Corporation (US) | 2014-08-28 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-0186190-B1 | BENZIMIDAZOLE DERIVATIVES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-26 | — | — | EP | disclosed |
| US-4663339-A | Acaricidal and insecticidal substituted 1-phenylalkylbenzimidazoles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0186190-A2 | Benzimidazole derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | HTT 1526/4885ALDH1A1 2404/4885CYP1A2 3815/4885 |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | LPO, NOTUM, FARS2 | HTT 2334/4885ALDH1A1 1503/4885CYP1A2 230/4885 |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | DOT1L, ASH1L, CARM1 | HTT 3604/4885ALDH1A1 1001/4885CYP1A2 4679/4885 |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | HTT 3604/4885ALDH1A1 1001/4885CYP1A2 4679/4885 |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | HTT 3033/4885ALDH1A1 1884/4885CYP1A2 4120/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | HTT 1526/4885ALDH1A1 2404/4885CYP1A2 3815/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | HTT 3604/4885ALDH1A1 1001/4885CYP1A2 4679/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | HTT 2852/4885ALDH1A1 592/4885CYP1A2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.